US Stocks Higher; Dow Rises Over 100 Points

U.S. stocks traded higher this morning, with the Dow Jones gaining over 100 points on Monday

Following the market opening Monday, the Dow traded up 0.35% to 33,592.23 while the NASDAQ rose 0.01% to 11,005.21. The S&P 500 also rose, gaining, 0.14% to 3,940.05.

Also check this: Volatility In Markets Increases Ahead Of Fed's Rate Decision

Leading and Lagging Sectors

Energy shares rose by 0.6% on Monday. Meanwhile, top gainers in the sector included Euronav NV EURN, up 8%, and Frontline Ltd. FRO, up 8%.

In trading on Monday, consumer discretionary shares fell by 0.7%.

Top Headline

 

Coupa Software Inc COUP announced it will be acquired by Thoma Bravo for $8 billion. Coupa also reported its third-quarter financial results.

Coupa entered into a definitive agreement to be acquired by Thoma Bravo in an all-cash transaction with an enterprise value of $8 billion. Under the terms of the agreement, Coupa shareholders will receive $81 per share in cash.

 

Equities Trading UP

Aptevo Therapeutics Inc. APVO shares shot up 66% to $5.68 after the company announced that APVO436, in combination with venetoclax and azacitidine, achieved a 100% clinical benefit rate in venetoclax treatment naïve AML patients.
Shares of China Jo-Jo Drugstores, Inc. CJJD got a boost, shooting 30% to $4.30 after jumping 53% on Friday.
Coupa Software Incorporated COUP shares were also up, gaining 27% to $78.75 after the company announced it will be acquired by Thoma Bravo for $8 billion.

 

Equities Trading DOWN

• Adicet Bio, Inc. ACET shares tumbled 42% to $9.95 after the company announced safety and efficacy data from its ongoing Phase 1 study of ADI-001 for the potential treatment of relapsed or refractory B-cell NHL.
• Shares of Affimed N.V.. AFMD were down 38% to $1.2601 after the company announced topline data from its Phase 2 REDIRECT study of AFM13 monotherapy in patients with advanced-stage relapsed/refractory peripheral T cell lymphoma.
• Ambrx Biopharma Inc. AMAM was down, falling 28% to $3.2640. Ambrx Biopharma shares jumped over 1,007% on Friday after the company announced preliminary Phase 2 results from its ACE-Breast-03 study showing a 57.1% overall response rate.

Also check out: S&P 500 Snaps 5-Session Losing Streak But Investor Sentiment Eases

Commodities

In commodity news, oil traded up 2.1% to $72.52 while gold traded down 0.8% at $1,797.20.

Silver traded down 0.6% to $23.57 on Monday while copper fell 2% to $3.8005.

 

Euro zone

European shares were lower today. The eurozone’s STOXX 600 fell 0.7%, London’s FTSE 100 fell 0.4% while Spain’s IBEX 35 Index fell 0.4%. The German DAX declined 0.6%, French CAC 40 fell 0.6% and Italy’s FTSE MIB Index fell 0.2%.

Industrial production in the UK came in unchanged from the previous month during the month of October. The UK trade deficit narrowed to GBP 1.8 billion in October from GBP 3.1 billion a month ago. The British economy grew by 0.5% in October from September, recording the biggest expansion in around one year.

 

Asia Pacific Markets

Asian markets closed lower on Monday, with the Japan’s Nikkei dropping 0.21% and Hong Kong’s Hang Seng Index dipping 2.20%. China’s Shanghai Composite Index fell 0.87%.

Producer prices in Japan climbed 9.3% year-over-year in November slowing from a revised 9.4% increase in October. Chinese total social increased to CNY 1.99 trillion in November from CNY 0.91 trillion in the prior month.

 

Economics

There were no major US economic releases Monday

Check out this: CNN Fear & Greed Index In 'Neutral' Zone After Dow Tumbles 300 Points

COVID-19 Update

The U.S. has the highest number of coronavirus cases and deaths in the world, reporting a total of 101,324,880 cases with around 1,109,850 deaths. India confirmed a total of at least 44,676,070 cases and 530,650 deaths, while France reported over 38,504,840 COVID-19 cases with 159,610 deaths. In total, there were at least 653,911,220 cases of COVID-19 worldwide with more than 6,658,980 deaths.